Solubility is a fundamental physico-chemical property with important applications to biological, chemical, pharmaceutical and environmental industries. Reliable solubility data require careful experimental measurements that are tedious, time consuming and costly, and this research area needs further investigation.
iour of drugs is studied within a wide polarity range, curves with one or two solubility peaks may be found. 6) Mota et al. 11) used the Non-random Two Liquid Segment Activity Coefficient (NRTL-SAC) model for predicting the solubility in pure solvents and solvent mixtures at 25-40°C. The model requires the melting data from the solid phase, T f , DH f and DC p . Limited experimental DC p values are available for drugs and this contribution is frequently ignored in solubility calculations.
11) The predictions did not agree well with the experimental data of paracetamol at high ethanol-in water ratios, a fact that was attributed to the appearance of a peak in the solubility profile, as was earlier reported. 13, 14) Bustamante and co-workers proposed a model to predict the solubility mole fraction ln X 2 of drugs showing two solubility peaks in solvent mixtures at a particular temperature. 15, 16) In this work we expand our earlier model to include in a single equation several temperatures and two solvent mixtures (Eq. 1):
T is the temperature, d 1 is the Hildebrand solubility parameter, d 1a and d 1b the acidic and basic partial solubility parameters of Karger et al., 17) and I is a variable indicator taking values of Iϭ1 and Iϭ0 for aqueous and non-aqueous mixtures, respectively.
For solvent mixtures, the Hildebrand and partial solubility parameters can be calculated as a linear combination of the d's of the pure solvents and the volume fraction of the solvents in the mixture. 18) The coefficients C 0 -C 5 are obtained from multiple linear regression, and the melting temperature and the heat of fusion are not required in the model. For a given drug, these are constant values included into the intercept C 0 . This is advantageous because some drugs decompose during melting and these thermodynamic magnitudes cannot be properly measured.
The terms included into the solubility model may be re- Equation 1 is tested to model the solubility behaviour of three antihelmintic drugs. Mebendazole (MBZ) is a benzimidazole (methyl (6-benzoyl-1H-benzimidazol-2-yl) carbamate) of broad spectrum used to treat infestations by worms. Mebendazole may exist as polymorphic forms A, B, and C. 19, 20) Metronidazole (MTZ) is a nitroimidazole (methyl 2-(2-methyl-5-nitro-1H-imidazol-1-yl) used mainly in the treatment of infections caused by anaerobic bacteria and protozoa. Thiabendazole (TBZ) is a benzimidazole (4-(1H-1,3-benzodiazol-2-yl)-1,3-thiazole), used as fungicide and parasiticide (Figs. 1-3) .
The experimental solubility of mebendazole (MBZ) was determined at several temperatures (5-35°C). The solubilities of metronidazole (MTZ) and thiabendazole (TBZ) were determined at 25°C, and the data at other temperatures can be found elsewhere.
21)

Experimental
Materials Mebendazole (MBZ), metronidazole (MTZ) and thiabendazole (TBZ) were purchased from Sigma-Aldrich (Steinheim, Germany) (batches 35H0610, 54H0407 and 65H0302; respectively). The solvents used were ethyl acetate, ethanol (spectrophotometric grade; Panreac, Monplet and Esteban, Barcelona, Spain) and double-distilled water.
Methods. Differential Scanning Calorimetry (DSC) Samples of about 5 milligrams (mg) were heated in aluminium pans under nitrogen gas purge in a differential scanning calorimeter (Mettler TA 4000, Switzerland). The thermal behaviour of the original powders of the drugs and that of the solid phases after equilibration with the pure solvents were analyzed at 5°C/min (or 10°C/min to check differences with heating rate). The solid non-dissolved phases were placed on filter papers and the solvent excess was gently evaporated at room temperature until constant weight. This procedure was chosen because more drastic conditions may remove solvent loosely bound to the crystals that may affect the thermal behaviour of the solid phase. 22) The experiments were performed in triplicate.
Fourier Transforms Infrared Spectroscopy (FT-IR) Fourier transform IR spectra were examined over the scanning range of 650-4000 cm Ϫ1 using a Spectrum 2000 spectrometer (Perkin Elmer, U.S.A.). The resolution was 1 cm
Ϫ1
. The spectra were recorded for mebendazole and for the crystals obtained after contact with water, ethanol and ethyl acetate. Samples of 2 mg were mixed with 100 mg of potassium bromide and gently ground in a mortar. The samples were analysed from disks of about 13 mm diameter prepared with KBr and compressed in a hydrostatic press at a force of 5 T for 2 min.
Solubility Determination Sealed flasks containing an excess of powder in the pure solvents and solvent mixtures were shaken in a temperature-controlled bath (Heto SH 02/100, Denmark; Ϯ0.1°C). The saturation concentration was determined from the asymptotic regions of the dissolution curves versus time. When equilibrium solubility was attained, the solid phase was removed by filtration (Durapore membranes, 0.2 mm pore size, Millipore Ibérica S.A., Spain). The drugs did not significantly adsorb onto the membranes. The clear solutions were diluted with ethanol 96% (v/v) and assayed in a double-beam spectrophotometer (Shimadzu UV-2001PC, U.S.A.). The measurements were performed at 247 nm for MBZ, 312 nm for MTZ and 300 nm for TBZ. The densities of the solutions were determined at each temperature in 10-ml pycnometers. All the experimental results are the average of at least three replicated experiments. The coefficient of variation is within 2% among replicated samples for the solubility measurements.
Results and Discussion
Solid Phase Characterization Table 1 summarizes the thermal events before and after equilibration of the drugs with the pure solvents. The peaks of fusion are T f ϭ160.82°C (DH f ϭ32.65 kJ/mol) for MTZ and T f ϭ300.7°C (DH f ϭ35.19 kJ/mol) for TBZ. The solid phases did not show new thermal effects after equilibration with the solvents, and the temperatures and enthalpies at the peaks are similar to those found for the three original powders.
Mebendazole may exist under three polymorphic forms, A, B and C, and the thermal effects obtained correspond to the most stable and less soluble Form A at room temperature (Fig. 4 ). The original powder shows an endothermic/exothermic transition (T 1 ϭ251.6-260°C, DHϭ77.33 kJ/mol) and a second endothermic peak (T 2 ϭ304°C, DHϭ78.23 kJ/mol) at a heating rate of 5°C/min. The temperature at the peaks is somewhat higher at 10°C/min (T 1 ϭ260.75°C and T 2 ϭ 315.52°C, respectively) due to the greater sensitivity and less resolution. De Villiers et al. 20) reported these two effects at 250-255°C and 330°C and Himmelreich et al. 23) found two endotherms at 235°C and 320°C (heating rate, 10°C/min). The thermograms of the mebendazole non-dissolved solid phase after equilibration with water, ethanol and ethyl acetate did not show new thermal events (Fig. 4) suggesting that the solvents do not induce solid phase changes. The FT-IR absorption spectrum is the preferred technique to identify the polymorphic forms of MBZ because they show characteristic differences in the shape and intensity of the major absorption bands at 3370 cm Ϫ1 for the -NH-group and at 1730 cm Ϫ1 for the -CϭO group. 20, 24) In addition, a characteristic strong absorption band at 1650 cm Ϫ1 from the -CNH-group can be also used. The values obtained in this work are similar to those reported for polymorph A (Table 2) . Solubility Profiles Tables 3 and 4 (Table 3 ). MBZ and MTZ show "chameleonic" behaviour, characterized by the appearance of two maxima at two distinct (higher and lower) polarity values whereas TBZ displays a single peak. ). Solubility profiles displaying one or two maxima have been reported for drugs within the polarity range covered by ethanol-water and ethanol-ethyl acetate mixtures. Curves with two maxima were found for more polar drugs with higher solubility parameter values such as caffeine and paracetamol. 5, 13) Solubility profiles with a single peak (usually in ethanol-ethyl acetate) were related to less polar drugs with lower solubility parameters as benzocaine.
14)
Relationships of Drug Solubility Parameter and Cosolvent Action The experimental solubility parameter of a drug d 2 can be determined from the Lin and Nash method, 25) using the solubility mole fraction of the drug X 2i in three or five pure solvents of known solubility parameters d 1i : Water, ethanol and ethyl acetate were used here ( Table 5) . The values of d 2 calculated from the Fedors group contribution method 26) are higher (Table 5 ) and nearer the solubility peak found in the more polar mixture (ethanol-water). The experimental values are closer to the peak obtained in the less polar mixture (ethanol-ethyl acetate). Although the solubility parameter values are different, both methods provide the same decreasing polarity trend for the drugs: MTZϾ TBZϾMBZ. Table 5 Table 5) .
The solubility enhancement varies with temperature in both mixtures and it is inversely related to the water solubility of the drugs: TBZϾMBZϾMTZ.
The ratios of the peak height ( Solubility Prediction Equation 1 is fitted to all the experimental data for each drug, including both mixtures (ethanol-water and ethanol-ethyl acetate) and all temperatures (Tables 3, 4) . The data used for MTZ and TBZ at 15, 20, 30 and 35°C can be found elsewere.
21) The following RMSE is the root mean squared error and n is the number of cases. Figures 5-7 show that the model is able to predict the different solubility profile shapes found experimentally, i.e., curves with two symmetrical (MTZ) or asymmetrical (MBZ) maxima, and with a single peak and a shoulder (TBZ).
To further test the prediction ability of the model, Eq. 1 is fitted to a smaller number of data, and the training equation is then used to predict solubility at other temperatures and co-solvent ratios not used to fit the equation. Unlike regression, prediction does not involve any fit of the data providing a better evaluation of the model. The prediction coefficient p 2 is strictly analogous to r 2 and is obtained as follows 15) : (6) where ln X 2 , ln X calc and ln X mean are the experimental, calculated and mean values, respectively. The training data in- All the regression coefficients are statistically significant and their values are comparable to those obtained with the whole data set (Eqs. [3] [4] [5] . The positive and negative signs on the coefficients are also consistent with the model as found for the whole data set. Equations 7-9 are used to predict the solubility at the remaining co-solvent ratios and temperatures. The prediction coefficients p 2 (Eq. 6) are in general larger than 0.99 except for metronidazole at 20°C. Equations 7-9 are able to predict different solubility profiles with one or two maxima using a limited number of data point, i.e. 20 data pair are used to predict more than 100 solubilities for each drug. Figure 8 shows a sample of the solubility profiles predicted at b) Experimental value from the Lin and Nash method. 25) c) No peak in ethanol-water. 25°C for MTZ, and MBZ and TBZ. Figure 9 displays the correlation between the experimental and predicted solubility values (Eqs. [7] [8] [9] for all drugs at all temperatures (nϭ329; r 2 ϭ0.99).
Conclusion
The single equation proposed here to model solubility curves with one or two maxima at several temperatures (Eq. 1) was able to reproduce the solubility profiles of all the drugs (r 2 larger than 0.96). To our knowledge there is not other model that combines two mixtures and several temperatures in a single equation. The model showed true predictive capability because the solubility curves can be calculated at other temperatures and co-solvent ratios from a small data set (for each drug, more than 100 solubility values were predicted from 20 experimental data). The ability prediction is useful to save experiments that are often expensive and time consuming. 
